172 related articles for article (PubMed ID: 35456021)
21. Screening and Development of Transglutaminase-2 Inhibitors and their Derivative as Anti-lung Cancer Agent by in silico and in vitro Approaches.
Parvatikar PP; Patil S; Hoskeri J; Swargam S; Kulkarni RV; Das KK
Curr Comput Aided Drug Des; 2022; 18(1):41-51. PubMed ID: 34225635
[TBL] [Abstract][Full Text] [Related]
22. Infection-driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cells.
Maffei B; Laverrière M; Wu Y; Triboulet S; Perrinet S; Duchateau M; Matondo M; Hollis RL; Gourley C; Rupp J; Keillor JW; Subtil A
EMBO J; 2020 Apr; 39(8):e102166. PubMed ID: 32134139
[TBL] [Abstract][Full Text] [Related]
23. Transglutaminase 2: Development of therapeutic antibodies reveals four inhibitory epitopes and confirms extracellular function in fibrotic remodelling.
Maamra M; Benayad OM; Matthews D; Kettleborough C; Atkinson J; Cain K; Bon H; Brand H; Parkinson M; Watson PF; Johnson TS
Br J Pharmacol; 2022 Jun; 179(11):2697-2712. PubMed ID: 34879432
[TBL] [Abstract][Full Text] [Related]
24. Neuronal and Endothelial Transglutaminase-2 Expression during Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Pearse DD; Otero PA; Diaz A; Pan X; Ghosh M
Neuroscience; 2021 May; 461():140-154. PubMed ID: 33253822
[TBL] [Abstract][Full Text] [Related]
25. Transglutaminase 2 mediates lung inflammation and remodeling by transforming growth factor beta 1
Kim YC; Kim J; Kim S; Bae B; Kim RL; Jeong EM; Cho SH; Kang HR
Exp Lung Res; 2021 Dec; 47(10):465-475. PubMed ID: 34818962
[TBL] [Abstract][Full Text] [Related]
26. A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis.
Wang Z; Perez M; Caja S; Melino G; Johnson TS; Lindfors K; Griffin M
Cell Death Dis; 2013 Sep; 4(9):e808. PubMed ID: 24052076
[TBL] [Abstract][Full Text] [Related]
27. Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia.
Stamnaes J; Dorum S; Fleckenstein B; Aeschlimann D; Sollid LM
Amino Acids; 2010 Nov; 39(5):1183-91. PubMed ID: 20300788
[TBL] [Abstract][Full Text] [Related]
28. Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses.
Stephens P; Grenard P; Aeschlimann P; Langley M; Blain E; Errington R; Kipling D; Thomas D; Aeschlimann D
J Cell Sci; 2004 Jul; 117(Pt 15):3389-403. PubMed ID: 15199098
[TBL] [Abstract][Full Text] [Related]
29. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice.
Popov Y; Sverdlov DY; Sharma AK; Bhaskar KR; Li S; Freitag TL; Lee J; Dieterich W; Melino G; Schuppan D
Gastroenterology; 2011 May; 140(5):1642-52. PubMed ID: 21277850
[TBL] [Abstract][Full Text] [Related]
30. Epitope-dependent Functional Effects of Celiac Disease Autoantibodies on Transglutaminase 2.
Hnida K; Stamnaes J; du Pré MF; Mysling S; Jørgensen TJ; Sollid LM; Iversen R
J Biol Chem; 2016 Dec; 291(49):25542-25552. PubMed ID: 27784785
[TBL] [Abstract][Full Text] [Related]
31. Transglutaminase 2 as a novel target in chronic kidney disease - Methods, mechanisms and pharmacological inhibition.
Prat-Duran J; Pinilla E; Nørregaard R; Simonsen U; Buus NH
Pharmacol Ther; 2021 Jun; 222():107787. PubMed ID: 33307141
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE
Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590
[TBL] [Abstract][Full Text] [Related]
33. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
34. GPR56 inhibits melanoma growth by internalizing and degrading its ligand TG2.
Yang L; Friedland S; Corson N; Xu L
Cancer Res; 2014 Feb; 74(4):1022-31. PubMed ID: 24356421
[TBL] [Abstract][Full Text] [Related]
35. Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2.
Johnson KB; Petersen-Jones H; Thompson JM; Hitomi K; Itoh M; Bakker EN; Johnson GV; Colak G; Watts SW
Am J Physiol Heart Circ Physiol; 2012 Apr; 302(7):H1355-66. PubMed ID: 22307675
[TBL] [Abstract][Full Text] [Related]
36. Inhibiting Transglutaminase 2 Mediates Kidney Fibrosis via Anti-Apoptosis.
Moon JJ; Choi Y; Kim KH; Seo A; Kwon S; Kim YC; Kim DK; Kim YS; Yang SH
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740367
[TBL] [Abstract][Full Text] [Related]
37. Urinary levels of pro-fibrotic transglutaminase 2 (TG2) may help predict progression of chronic kidney disease.
Da Silva Lodge M; Pullen N; Pereira M; Johnson TS
PLoS One; 2022; 17(1):e0262104. PubMed ID: 35041708
[TBL] [Abstract][Full Text] [Related]
38. Transglutaminase 2 mediates UVB-induced matrix metalloproteinase-1 expression by inhibiting nuclear p65 degradation in dermal fibroblasts.
Lee SJ; Lee KB; Hong AY; Son YH; Lee DH; Jeong EM; Kim IG
Exp Dermatol; 2022 May; 31(5):743-752. PubMed ID: 34882846
[TBL] [Abstract][Full Text] [Related]
39. Transglutaminase 2 kinase activity facilitates protein kinase A-induced phosphorylation of retinoblastoma protein.
Mishra S; Melino G; Murphy LJ
J Biol Chem; 2007 Jun; 282(25):18108-18115. PubMed ID: 17478427
[TBL] [Abstract][Full Text] [Related]
40. Effect of exogenous wild-type p53 on melanoma cell death pathways induced by irradiation at different linear energy transfer.
Min FL; Zhang H; Li WJ; Gao QX; Zhou GM
In Vitro Cell Dev Biol Anim; 2005; 41(8-9):284-8. PubMed ID: 16409115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
